These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21139240)

  • 1. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(12):1999-2002. PubMed ID: 21139240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
    Zohar J; Keegstra H; Barrelet L
    Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA
    Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
    Bondolfi G; Chautems C; Rochat B; Bertschy G; Baumann P
    Psychopharmacology (Berl); 1996 Dec; 128(4):421-5. PubMed ID: 8986013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T3 augmentation of SSRI resistant depression.
    Abraham G; Milev R; Stuart Lawson J
    J Affect Disord; 2006 Apr; 91(2-3):211-5. PubMed ID: 16483669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders.
    Sonawalla SB; Spillmann MK; Kolsky AR; Alpert JE; Nierenberg AA; Rosenbaum JF; Fava M
    J Clin Psychiatry; 1999 Sep; 60(9):580-3. PubMed ID: 10520975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
    Dalery J; Honig A
    Hum Psychopharmacol; 2003 Jul; 18(5):379-84. PubMed ID: 12858325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis.
    Rausch JL; Hobby HM; Shendarkar N; Johnson ME; Li J
    J Clin Psychopharmacol; 2001 Apr; 21(2):139-42. PubMed ID: 11270909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
    Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl1 polymorphism of the glucocorticoid receptor gene and treatment response to milnacipran and fluvoxamine in Japanese patients with depression.
    Takahashi H; Yoshida K; Higuchi H; Kamata M; Inoue K; Suzuki T; Ishigooka J
    Neuropsychobiology; 2014; 70(3):173-80. PubMed ID: 25358426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
    Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
    Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell triiodothyronine uptake in unipolar major depression: effect of a chronic antidepressant treatment.
    Moreau X; Azorin JM; Lejeune PJ; Jeanningros R
    Prog Neuropsychopharmacol Biol Psychiatry; 2000 Jan; 24(1):23-35. PubMed ID: 10659981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis at the first episode to differentiate antidepressant treatment responses in patients with mood and anxiety disorders.
    de Kemp EC; Moleman P; Hoogduin CA; Broekman TG; Goedhart A; Schaap CP; van den Berg PC
    Psychopharmacology (Berl); 2002 Feb; 160(1):67-73. PubMed ID: 11862375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
    Hirose S; Ashby CR
    J Clin Psychiatry; 2002 Aug; 63(8):733-6. PubMed ID: 12197455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.
    Yoshida K; Higuchi H; Kamata M; Takahashi H; Inoue K; Suzuki T; Itoh K; Ozaki N
    J Psychopharmacol; 2007 Aug; 21(6):650-6. PubMed ID: 17092970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
    Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
    Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.